Heart is the most importanat muscle in human body. Its work ensures the flow of blood to all parts of the body. Heart and cardiovascular diseases are ithe most prevalent worldwide causing up to 50 % mortality in developed countries. Large number of heart diseases lead to heart failure. Some degrees of heart failure can be treated with medication, while other require heart transplantation. However, the number of donor organs is far lower than the real needs of patients, and all patients are not candidates for transplantation. Therefore, an initiative for implanting the total artificial heart (TAH) was started in USA, and first implantation was preformed in 1969. Today there are two types of TAH in use, " SynCardia" and "AbioCor". The main difference between these two devices is that "SynCardia" is connected to an external power source, while "AbioCor" is not. "SynCardia" has tubes running through holes in the anterior abdominal wall, leaving the body to an external power source. "AbioCor" is completely contained in the chest. Indications for TAH are last phase biventricular heart failure (which can be caused by: cardiomyopathies, cardiogenic shock, a massive heart attack, congenital heart defects in adults, amyloidosis), graft rejection, patients who need transplantation. Implantation of TAH is a challenging surgical procedure. It is performed in seven steps: sternotomy and surgical access, removal of the heart, preparation of anastomoses, anastomoses, the appointment of the ventricles and the closure of the chest. Complications of surgery are blood clots, bleeding, infection and device failures.